secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001104659-26-025901
Event type: debt
Sentiment:  negative
Materiality: 0.90
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud

Acura Pharma gets $300K more loans from AD Pharma, warns of possible shutdown if no financing by March 2026
--------------------------------------------------------------------------------

- Received $100,000 loans on Feb 6, Feb 13, and Mar 9, 2026 from Abuse Deterrent Pharma, LLC (AD Pharma), increasing principal balance to $9,894,279.
- Note bears interest at 5.25% per annum, with overdue amounts accruing at 7.5%; events of default include bankruptcy, payment failure, and admitted inability to pay debts.
- AD Pharma directly owns approximately 65% of Acura's outstanding common stock as of Feb 28, 2026, and is controlled by Mr. Schutte.
- If additional financing is not secured by end of March 2026, Acura will need to scale back operations, including furloughs and layoffs, or terminate operations and seek bankruptcy protection.
- No assurance of receiving more funds; failure could result in complete loss of shareholder value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/0001104659-26-025901-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465926025901/tm268475d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-025901

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer